Literature DB >> 1949908

Metabolism of the chloroethylnitrosoureas.

A Lemoine1, C Lucas, R M Ings.   

Abstract

1. The chemical degradation and metabolism of the 2-chloroethylnitrosoureas (CENUSs) have been critically reviewed with the objective of gaining a better understanding of factors that could aid in the design of new, more effective, anticancer drugs. 2. The CENUs are chemically unstable under normal physiological conditions and can rapidly degrade to give a variety of reactive intermediates capable of carbamoylating proteins and/or alkylating both proteins and DNA. 3. Carbamoylation is thought to make a minimal contribution to the cytotoxic effect of the CENUs, although it may be involved in some of the unwanted side-effects. It would seem desirable, therefore, to design new CENUs with low carbamoylating activity. 4. The main action of the CENUs is by alkylation of DNA via a chloroethyldiazo-hydroxide intermediate. Chloroethylation is important, as opposed to hydroxyethylation, since the former leads to inter-strand DNA cross-linking via an intramolecular rearrangement with the removal of chloride. It is this inter-strand cross-linking which prevents subsequent DNA repair and loss of cytotoxicity. 5. Metabolism usually, although not exclusively, leads to deactivation of the CENUs either by dechlorination or denitrosation of the molecule, generally with the former being the dominant route. These reactions occur very rapidly, and before chemical degradation can take place, and can be an important determinant in the final cytotoxicity. Moreover, both these pathways involve the cytochrome P-450 system and can be induced with phenobarbital.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1949908     DOI: 10.3109/00498259109039517

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  7 in total

1.  Inhibition of carbamyl phosphate synthetase-I and glutamine synthetase by hepatotoxic doses of acetaminophen in mice.

Authors:  S Gupta; L K Rogers; S K Taylor; C V Smith
Journal:  Toxicol Appl Pharmacol       Date:  1997-10       Impact factor: 4.219

2.  Alleviation of 1,N6-ethanoadenine genotoxicity by the Escherichia coli adaptive response protein AlkB.

Authors:  Lauren E Frick; James C Delaney; Cintyu Wong; Catherine L Drennan; John M Essigmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

3.  Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.

Authors:  B Tranchand; C Lucas; P Biron; B Giroux; B Gordon; R Richards; P Solere; N Roux; E Evene; F Mornex
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.

Authors:  R Fety; C Lucas; P Solere; V Cour; J Vignoud
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.

Authors:  Manny D Bacolod; Randy Fehdrau; Stewart P Johnson; Nancy S Bullock; Darell D Bigner; Michael Colvin; Henry S Friedman
Journal:  Cancer Chemother Pharmacol       Date:  2008-07-17       Impact factor: 3.333

6.  Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma.

Authors:  E Debiton; C Cussac-Buchdhal; E Mounetou; M Rapp; J M Dupuy; J C Maurizis; A Veyre; J C Madelmont
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.

Authors:  Thushara Chakkath; Sidonie Lavergne; Timothy M Fan; David Bunick; Levent Dirikolu
Journal:  Vet Sci       Date:  2015-04-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.